title: Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
abstract: BACKGROUND
  The Health Belief Model states that medication adherence is primarily determined by beliefs (i.e., perceptions of: adherence costs and benefits, susceptibility, and outcome severity), yet little is known regarding the model's longitudinal utility.
  
  
  OBJECTIVE
  To examine the longitudinal utility of the Health Belief Model in explaining non-adherence with antipsychotic medication in clinical settings in early-episode schizophrenia.
  
  
  METHODS
  Participants (n=112) with a DSM-IV diagnosis of schizophrenia (n=84, 75%) or schizoaffective disorder (n=28, 25%) participated in a four wave six month study. Participants were assessed on adherence (Visual Analog Scale for Assessing Treatment Adherence), symptom severity indices, the Drug Attitudes Inventory, and extrapyramidal side-effects.
  
  
  RESULTS
  Unlike non/partially adherent participants, adherent participants showed statistically significantly (p<.05) more: insight into illness, awareness of the need for medication, positive perceptions of trust in the doctor-patient therapeutic alliance, perceived family involvement in pharmacological treatment, positive attitudes towards medication in the family and fewer adverse events. Adherence rates at endpoint did not differ between typical, atypical and mixed antipsychotic medication groups. Structural equation modeling showed that over 6 months symptom severity, awareness for the need of medication and attitudes to medication predicted adherence. Awareness of the need of medication, awareness of social consequences, participant's perceived trust in physician and the severity of negative symptoms all predicted attitudes to medication that in turn predicted adherence.
  
  
  CONCLUSIONS
  The current results partly support the adherence Health Belief Model, and emphasize the role of attitudes toward medication as a predictor of adherence.
authors.affiliation: Mental Health Services, Ministry of Health, Jerusalem, Israel. baloush18@gmail.com
authors.forename: Vered
authors.initials: V
authors.lastname: Baloush-Kleinman
authors.forename: Stephen Z
authors.initials: SZ
authors.lastname: Levine
authors.forename: David
authors.initials: D
authors.lastname: Roe
authors.forename: Dan
authors.initials: D
authors.lastname: Shnitt
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
authors.forename: Michael
authors.initials: M
authors.lastname: Poyurovsky
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D010147:Pain Measurement; D010351:Patient Discharge / Q000706:statistics & numerical data; D011237:Predictive Value of Tests; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy / Q000523:psychology; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents